Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2591258 | 0.78 | GAA (0.49) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL6755229 | 0.77 | HTT (0.44) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL4045244 | 0.77 | HTT (0.44) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL13208612 | 0.74 | HTT (0.42) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL25836668 | 0.74 | HTT (0.42) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL633115 | 0.74 | HTT (0.42) | HTTGAAKDM4ETSHRSMN1; SMN2 | |
| SCHEMBL502375 | 0.74 | HTT (0.39) | HTTGAAKDM4ETSHR | |
| SCHEMBL7260183 | 0.74 | HTT (0.39) | HTTGAAKDM4ETSHR | |
| SCHEMBL12256767 | 0.73 | GAA (0.33) | GAA | |
| SCHEMBL9951819 | 0.73 | HTT (0.41) | HTTGAAKDM4ETSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745129-A2 | COMPOUND HAVING CYCLIC STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2026-05-20 | — | — | EP | disclosed |
| EP-3682881-B1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO CO LTD (JP) | 2026-04-01 | — | — | EP | disclosed |
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4605397-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | Nuvalent, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| CN-120035594-A | Heteroaromatic macrocyclic ether chemotherapeutic agents | 纽威伦特公司 | 2025-05-23 | — | — | CN | disclosed |
| US-12297187-B2 | Compound having cyclic structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-05-13 | — | — | US | disclosed |
| WO-2024120466-A1 | MONOSACCARIDES, PHARMACEUTICAL COMPOSITIONS, AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | SURIO THERAPEUTICS CO., LTD (CN) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024086634-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| CN-111094255-B | Compounds having cyclic structures | 第一三共株式会社 | 2023-10-03 | — | — | CN | disclosed |
| WO-2005105791-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | disclosed |
| US-20040192666-A1 | Nonnucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2004-09-30 | — | — | US | disclosed |
| WO-2004074257-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-02 | — | — | WO | disclosed |
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| US-6503935-B1 | Treating urinary incontinence or retrograde ejaculation | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
| EP-1259491-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | Abbott Laboratories (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060802-A1 | 4-IMIDAZOLE DERIVATIVES OF BENZYL AND RESTRICTED BENZYL SULFONAMIDES, SULFAMIDES, UREAS, CARBAMATES, AND AMIDES AND THEIR USE AS ALPHA-1A AGONISTS | ABBOTT LABORATORIES (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-1102754-A1 | IMIDAZOLES AND RELATED COMPOUNDS AS ALPHA-1A AGONISTS | ABBOTT LABORATORIES (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007997-A1 | IMIDAZOLES AND RELATED COMPOUNDS AS α1A AGONISTS | ABBOTT LABORATORIES (US) | 2000-02-17 | — | — | WO | disclosed |
| US-5475113-A | Treatment of skin disorders, skin cancer | ALLERGAN, INC. (US) | 1995-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326769-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | ROS1, MCL1, ALK | HTT 2497/4885GAA 822/4885KDM4E 1802/4885 |
| US-12297187-B2 | Compound having cyclic structure | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | HTT 1220/4885GAA 2387/4885KDM4E 1061/4885 |
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | HTT 4621/4885GAA 2831/4885KDM4E 823/4885 |
| US-20040192666-A1 | Nonnucleoside reverse transcriptase inhibitors | POLRMT, RRM2B, RRM2 | HTT 3052/4885GAA 620/4885KDM4E 2175/4885 |
| US-20230331700-A1 | COMPOUND HAVING CYCLIC STRUCTURE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ECE1, IL1B | HTT 1220/4885GAA 2387/4885KDM4E 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.